IMGN - イミュノジェン （ImmunoGen Inc.）

https://www.investing.com/news/assorted/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-432SI-3040566

IMGN has seen its SMA50 which is now -8.94%. In looking the SMA 200 we see that the stock has seen a -17.64%. MBC has seen its SMA50 which is … The post Tiling stocks: ImmunoGen, Inc. (NASDAQ:IMGN 1.25%), MasterBrand, Inc. (NYSE:MBC -2.04%) appeared first on Stocks Equity .

ImmunoGen Inc. (NASDAQ:IMGN) has a beta value of 0.93 and has seen 2.94 million shares traded in the last trading session. The company, currently valued at $944.08M, closed the last trade at $4.20 per share which meant it gained $0.03 on the day or 0.72% during that session. The IMGN stock price is -57.86% off … An In-Depth Look At The ImmunoGen Inc. (IMGN) Stock Read More »

IMGN has seen its SMA50 which is now -1.10%. In looking the SMA 200 we see that the stock has seen a -9.27%. WE has seen its SMA50 which is … The post Outrageous stocks: ImmunoGen, Inc. (NASDAQ:IMGN), WeWork Inc. (NYSE:WE) appeared first on Stocks Equity .

ImmunoGen Inc (NASDAQ:IMGN) Q4 2022 Earnings Call dated Mar. 01, 2023.

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. The two NMEs that were okayed in November include Provention Bio, Inc.’s (NASDAQ: PRVB ) Tzield, approved for delaying the onset of stage-3, type-1 diabetes, and ImmunoGen Inc.’s (NASDAQ: IMGN ) mirvetuximab soravtansine monotherapy – a treatment for recurrent ovarian cancer resistant to platinum therapy. On the flip side, Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) received a complete response letter for its lung cancer drug application , prompting the company to pull the plug on the program. The iShares Biotechnology ETF (NASDAQ: IBB ), an exchange-traded fund tracking mostly large-cap biotechs, is down about 10% year-to-date, reflecting the travails faced by the sector. Benzinga has previewed December’s Prescription Drug User Fee Act dates — deadlines fixed by the FDA to communicate its decision about the approval or non-approval of a drug.

ImmunoGen''s Elahere recently received accelerated approval in FRα-high, platinum-resistant ovarian cancer and sports first-mover advantage. Read why IMGN is a Buy.

In the latest trading session, 1.17 million ImmunoGen Inc. (NASDAQ:IMGN) shares changed hands as the company’s beta touched 1.03. With the company’s most recent per share price at $5.17 changing hands around $0.02 or 0.39% at last look, the market valuation stands at $1.17B. IMGN’s current price is a discount, trading about -50.29% off its … ImmunoGen Inc.’s (NASDAQ: IMGN) Stock Could Appreciate By -325.53% Read More »

Immunogen (NASDAQ: IMGN ) brought in sales totaling $15.38 million during Q3 according to data provided by Benzinga Pro . However, earnings decreased 25.37%, resulting in a loss of $77.75 million. In Q2, Immunogen brought in $14.16 million in sales but lost $62.02 million in earnings. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and … Full story available on Benzinga.com

ImmunoGen recently gained the accelerated approval of Elahere for resistant ovarian cancers with high FRA expression. See why I''ve downgraded IMGN stock to a Buy.

ImmunoGen Inc. (NASDAQ:IMGN) traded at $5.62 at close of the session on Tuesday, 11/01/22, made a downward move of -5.39% on its previous day’s price. Looking at the stock we see that its previous close was $5.94 and the beta (5Y monthly) reads 0.98 with the day’s price range being $5.33 – $5.99. In terms … ImmunoGen Inc.’s (NASDAQ:IMGN) Stock Is Down -5.39%, But Is It Capable Of A Rally? Read More »

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Departure of Chief Commercial Officer

ImmunoGen has a critical PDUFA date next month, based on more or less strong data in a patient population with high unmet need. Read why IMGN is a Hold.

In Tuesday’s session, ImmunoGen Inc. (NASDAQ:IMGN) marked $6.05 per share, up from $6.00 in the previous session. While ImmunoGen Inc. has overperformed by 0.83%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IMGN rose by 3.24%, with highs and lows ranging from $7.77 to $3.10, whereas […]

The trading price of ImmunoGen Inc. (NASDAQ:IMGN) closed lower on Monday, October 24, closing at $6.00, -2.28% lower than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $5.945 and $6.245. In examining the 52-week price action we see that the stock hit a 52-week high … At What Point In Time Would I Choose To Purchase ImmunoGen Inc. (NASDAQ: IMGN) Stock? Read More »